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I. Introduction
Current clinical IMRT treatment planning is largely based on computed tomography (CT) imaging, which provides geometric information about the tumor and surrounding organs-atrisk (OARs). Treatment planning using CT imaging implicitly assumes that the tumor is 40 biologically homogeneous and aims to deliver a uniform dose [1] as this results in the optimal tumor control probability (TCP). [2, 3] Functional imaging such as positron emission tomography (PET) can provide insight into the heterogeneity of the tumor. [4] This heterogeneity of the tumor requires a non-uniform dose distribution in order to maximize TCP. [3, 5] Non-uniform dose distributions are also 45 being explored in a large multi-center clinical trial (RTOG1106). How to best utilize PET information to determine a heterogeneous dose distribution remains an open question. A number of researchers have proposed a tracer-independent linear relationship to transform the PET signal from a biological image to a desired heterogeneous dose distribution [1, [6] [7] [8] [9] , but it has also been suggested that a linear transformation may lead to unnecessary 50 overestimations of the desired dose. [10] Yang and Xing [11] calculated heterogeneous dose distributions required to maximize TCP given voxel-specific radiobiological parameters under the linear-quadratic (LQ) model. South et al.
[12] developed a theoretical framework to derive heterogeneous dose distributions based on functional imaging. A follow-up study by South et al. [13] applied this theoretical framework to PET imaging using fluorodeoxyglucose 55 (FDG) as a tracer to ultimately describe a heterogeneous distribution reflecting radiosensitivity. We follow a similar framework as South et al. [13] in this study to translate the PET image map to a desired heterogeneous dose distribution.
Boellaard [14] presents a comprehensive list of uncertainties affecting PET images, including the patient's blood glucose level, patient motion, inflammation, uptake period, scan 60 acquisition parameters, image reconstruction parameters, region of interest, and blood glucose level correction. These uncertainties, in turn, affect our understanding of the true biological activity. Thus, any treatment planning paradigm that uses PET imaging to derive a heterogeneous dose distribution must consider the inherent uncertainty in the PET signal.
A few studies have considered incorporating uncertainty into a biologically based treat-ment planning process. Kåver et al. [15] compared the use of stochastic optimization and margins on the biological parameters to maximize the expected probability of uncomplicated treatment. Witte et al. [16] addressed geometric uncertainties when using heterogeneous dose distributions in a probabilistic optimization model, where random and systematic (positional) errors were approximated using isotropic Gaussian kernels.
70
Robust optimization methods form another class of methods that aim to mitigate the effects of uncertainty in treatment planning. Such methods have been applied to non-biological IMRT treatment planning for interfraction uncertainty (e.g., setup error) [17, 18] and intrafraction uncertainty (e.g., tumor motion). [19] [20] [21] [22] [23] [24] [25] [26] Robust optimization methods have also been developed for intensity-modulated proton therapy. [27] [28] [29] [30] 
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In this paper, we develop the first robust optimization approach for PET-based treatment planning. We assume that the PET signal represents tumor heterogeneity, thus requiring a voxel-specific heterogeneous dose distribution. However, uncertainty in the PET signal can affect the overall treatment quality; if the true signal is higher than measured, we may be underdosing the tumor and if it is lower than measured, we may miss out on an opportunity 80 for improved sparing. Our approach accounts for uncertainty in the PET signal using a cardinality-based robust optimization model. [31] Our model is based on dose and does not optimize TCP directly. TCP is measured after the optimization models are solved. We apply our framework to a clinical lung case with PET information from Princess Margaret Cancer Centre in Toronto, Canada. We do not explicitly consider the effect of motion blurring on 85 the dose-influence matrix, but the effects of motion on the PET signal can be implicitly captured in our model.
II. Methods and materials
We assume that a voxel-specific standardized uptake value (SUV) obtained from a FDG-PET image is used to generate a heterogeneous desired dose. We aim to achieve this distri-90 bution using both non-robust and robust optimization methods. The two methods are then compared through a simulation study considering changes in SUV.
FDG uptake is hypothesized to be affected by a number of biological processes including radioresistance, [32] proliferation, [33] cell density, [34] and hypoxia. [35] [36] [37] Hotspots of survival. [32, 38] The optimization model we present is tracer-independent and only requires a voxel-specific desired dose distribution. The relationship we assume between FDG and desired dose is given in the Appendix. Note that as long as the values of the tracer observed in the image can be converted to a desired dose distribution, it can be used in our framework.
A. Model of SUV uncertainty
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We assume that the true SUV is not directly observed due to uncertainty in the image.
[14] We define θ i to be the nominal (i.e., observed) SUV in voxel i of the PET image. The true (i.e., unobserved) SUV for voxel i,θ i , resides in an interval U i = [θ i −θ i , θ i +θ i ], wherê θ i is the maximum absolute deviation from the nominal SUV for voxel i.
The values θ i andθ i will be used to determine a dose distribution for treatment planning.
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Since the true SUV value is unknown, the dose that should have been given may be different from the nominal dose distribution, which is derived from the observed SUV. Thus, if we design a treatment using the nominal heterogeneous dose distribution, we may underdose or overdose certain voxels with respect to the dose that should have been given.
B. Mathematical formulation
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We develop a robust optimization framework for treatment planning in the presence of PET signal uncertainty based on the "budget of protection" model described in [31] . Our goal is to demonstrate a proof of concept for the value of robustness in the presence of PET signal uncertainty. As such, we use a simple penalty-based linear model that approximates a treatment planning formulation, but omits many of the more sophisticated features of 115 clinical formulations for the sake of simplicity.
Let i, j, and k index voxels, beamlets, and structures, respectively. Let I k be the set of all voxels in structure k, O be the index set of all organs-at-risk (OARs), I T be the set of all tumor voxels, I O be the set of all OAR voxels, and J be the set of all beamlets. Let y i and z measure the underdose to voxel i and maximum underdose to the clinical target volume (CTV), respectively. Let w j be the intensity of beamlet j. Let D ij be the influence matrix describing the dose from unit intensity of beamlet j to voxel i. Let f (θ i ) be the desired dose to voxel i, given SUV θ i . Let U i and L i be the upper and lower bounds on the dose to voxel i, respectively. Let µ k be an upper bound on the mean dose to OAR k. We will refer to 
The objective (1a) minimizes a weighted combination of the total absolute deviation (underdose) from the voxel-specific desired dose for all target voxels and the total dose to the OARs. Parameters λ − , λ, λ O are the weights for penalizing underdose, maximum underdose, and OAR dose, respectively. Constraint (1b) models the underdose computation.
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Constraint (1c) models the maximum underdose computation. Constraint (1d) bounds the upper and lower doses to every OAR voxel. Constraint (1e) limits the mean dose for each OAR. Since Formulation (1) assumes no uncertainty in the underlying radiobiological parameters, a treatment that is able to deliver at least the desired dose to all CTV voxels will generate a voxel TCP of 0.99999, according to our TCP model in the Appendix.
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The robust formulation accounts for SUV uncertainty and builds on Formulation (1).
First, let f (θ i ) be the desired dose for voxel i associated with the uncertain SUVθ i , which we use in place of f (θ i ) in constraint (1b). Second, to facilitate the comparison of our robust model with the nominal model, we require the robust model to deliver a mean dose to the tumor that is the same as what is delivered in the nominal model. Thus, after solving the nominal model we calculate the mean tumor dose, which we define as Ω, and include a constraint which holds the mean CTV dose delivered by the robust solution equal to Ω. This ensures an unbiased comparison between different models because a simple boost dose to all voxels in the tumor will result in an increase in TCP. By holding the mean dose constant, we know that the improvement in TCP is a result of the redistribution of dose rather than a boost dose. Of course, a boost dose can be included to further improve TCP if possible.
These two changes to the nominal model are implemented by eliminating constraint (1b) in
Formulation (1) and adding the following constraints:
Since U i is an interval, a formulation including the constraint (2a) is not directly solvable as a linear program. However, we can easily reformulate it into a tractable linear program.
Our model assumes that each voxel's SUV may deviate from its nominal value; however, the total number of voxels that will deviate (and conspire to produce a worst-case effect) is bounded. We introduce a parameter γ i ∈ [0, 1] for each constraint involving U i to model the extent of the SUV change of voxel i. For example, γ i = 0 models the belief that voxel i will remain at its nominal SUV θ i and therefore only require the corresponding nominal desired dose, while γ i = 1 models the belief that voxel i will realize its worst-case (largest) SUV θ i +θ i and therefore require a higher dose to achieve the same TCP. Formulation (3) shows the linear robust formulation. A solution to this formulation is called the robust solution or robust plan.
If we allow γ i to be decision variables that can be optimized simultaneously with the beamlet intensities w j , the optimization engine will chose values for γ i in an optimistic (i.e., not worst-case) manner. Instead, to ensure that Formulation (3) is protecting against a worst-case realization of the SUV, we formulate an auxiliary optimization problem (4) that identifies the worst-case combination of voxels to change SUV and chooses the γ i values accordingly within an overall budget of Γ. Model (4) only considers the worst-case underdose as that is more important in terms of TCP robustness.
The value Γ can be interpreted as the maximum number of voxels that we expect to change their SUV to their worst-case values. Therefore Γ need not be larger than Γ max := |I T | where we assume all tumor voxels can change their SUV to their worst-case values. Given a particular Γ, the auxiliary problem (4) is solved first to find the optimal γ * i values, which are then used as input to Formulation (3). Note that Formulation (4) is an instance of the continuous knapsack problem, for which it is known that the greedy solution is optimal.
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That is, if the values of f (θ i +θ i ) − f (θ i ) are ranked in descending order, the optimal solution is γ * i = 1 for i = 1, . . . Γ and γ * Γ = Γ − Γ (in the case Γ is not integer). Hence, the effort required to solve Formulation (4) is minimal. Overall, the parameter Γ provides flexibility and allows a treatment planner to adjust his or her level of conservatism when designing the robust treatment.
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C. Patient data and optimization parameters
The exhale phase of a combined 4D FDG-PET/CT dataset was exported into the Computational Environment for Radiotherapy Research (CERR), in order to generate the dose influence matrices necessary for optimization. [39] The 4D data alleviates blur due to respiratory motion. The SUV of each voxel from the PET image was converted into a voxel-specific 145 desired dose distribution as described in the Appendix.
The penalty parameters were set as follows: λ − = 1000, λ = 100, 000, λ O = 1. Mean and maximum dose constraints were obtained from the QUANTEC series of papers [40] and clinical protocols at Princess Margaret Cancer Center (see Table II ). For the target, we set an upper limit of 1.4 times the desired dose on each voxel.
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For the robust formulation, we set Ω = 83.25 Gy, which is the mean tumor dose of the solution to the nominal formulation. We employed a coplanar equispaced 7 beam configuration for the two optimization models. We assumed a beamlet size of 1 cm × 1 cm. The models were solved using CPLEX 12 on a remote computing cluster using a node with a 2.27 Ghz Intel Xeon 10 core processor and 252 GB of RAM. All models solved in under one 
D. Simulating SUV changes to evaluate optimization results
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Once we determine an optimal fluence map from the nominal and robust formulations, we evaluate the dosimetric consequences of the realization of different SUV. We present two approaches to simulate SUV changes, depending on whether the voxels are uncorrelated or correlated.
Uncorrelated voxels 170
The first simulation assumes that randomly chosen voxels will realize their worst-case SUV (the maximum value θ i +θ i in the interval). This will result in underdosing if we only provided the nominal dose to the voxels. Boellaard [14] provides the typical ranges and maximum effect of many factors that can affect a PET signal, and although they may all affect the image, some of their interactions may cancel out. In the absence of more detailed data about the statistical distribution of each factor's effect, we setθ i to 0.6θ i as a conservative estimate of the worst-case effect. We simulated 2000 realizations for this scenario, each representing a random set of voxels that realize a change to their worst-case SUVs.
Correlated voxels
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The second method to simulate SUV changes assumes that voxels in close proximity will be correlated and thus their SUV deviations will move together. We consider the CTV to be composed of seven nested shells each of 4 mm thickness. We assume the outermost shell will have the highest uncertainty due to its proximity to neighboring non-target structures. The uncertainty decreases as we move from the outermost shell to the innermost shell. Table I 185 outlines the size of the uncertainty half-interval (i.e.,θ i ) for each shell. We only considered voxels potentially increasing in SUV. The simulation chooses all voxels to realize a positive change from their nominal SUV, thus representing a correlated effect. We investigate the effects if all voxels realize a positive change to a fraction of their maximum SUV within the specified range. Specifically, all voxels will realize an SUV of θ i + δθ i for various δ ∈ [0, 1].
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Note that this experiment represents any source of uncertainty that causes the voxel SUVs to move in the same direction.
III. Results
A. Uncorrelated voxels plans that satisfied the clinical limits using both the nominal and robust models, although as expected the robust plans had slightly higher (but still acceptable) lung dose.
Naturally, there is a trade-off between TCP and OAR sparing. In Figure 2 , the x-axis shows the mean dose to the lung, while the y-axis shows the mean TCP value over all simulated realizations. The dose to the lung only changes with the value of Γ and not 220 with each simulated realization of SUV (since the simulated SUV changes only occur in the target). As previously observed, there is an increase in minimum TCP and decrease in variance as we increase the value of Γ. However, the mean lung dose increases as well. 
B. Correlated voxels
IV. Discussion
It is important to note that the robust model maintains the same level of mean tumor dose as the nominal model. Simply increasing the beamlet intensities from the nominal solution by a uniform factor will lead to an improvement in TCP since dose to the tumor will increase. However, this action will also violate some of the maximum dose limits on the OARs. On 235 the other hand, our robust solution is able to obtain an improvement in TCP through the intelligent redistribution of dose, rather than a naive increase of it. In practice, redistribution of the dose should be done only if a desired minimum dose can be maintained in the tumor.
Ideally, a boost dose would be given as well to maximize the benefit. We demonstrate the use of a redistribution here simply to have a fair comparison between the robust and nominal 240 solutions. Even with this redistribution, the minimum dose in the CTV was at least 97% of the minimum desired dose (corresponding to SUV of 0). Overall, the redistribution was fairly modest -taking a small amount of dose from many colder voxels to give to fewer hot voxels -but still yielded a non-trivial improvement in TCP. It is important to maintain a certain minimum dose level to the target, especially when dose may be redistributed away 245 from voxels that may actually be "hotter" than they appear on the image. Also, although all OAR dose/QUANTEC limits are met for all robust solutions, a more difficult case may require the relaxation of some constraints or a penalized objective on normal tissue dose. voxel changing its SUV, possibly to worst-case values. This is a promising result because it means that we may be able to achieve improved robustness without giving up too much in terms of healthy tissue dose. This type of robustness result is common in the literature, where accounting for a modest amount of uncertainty is sufficient to change the structure of the robust solution so that other uncertain scenarios are now also protected against (e.g.,
[20]).
There is another reason why accounting for a modest amount of robustness seems to provide most of the protection of a fully conservative solution, specific to the models in this paper. The reason is because the solution to the auxiliary problem essentially ranks the voxels in decreasing order of worst-case deviation from the nominal SUV and selects 265 voxels to protect in that order. Therefore, larger values of Γ will include the protection of voxels that deviate less and less from their nominal SUV value. Another byproduct of the current approach is that we are essentially protecting against the "hottest" voxels. Because of our assumption in the uncorrelated case that the size of the uncertainty half-interval is an increasing function of nominal SUV, the rank-ordering induced by the auxiliary problem can It is important to emphasize that the Γ thresholds observed in this paper may not be generalizable to every patient. The purpose of this paper is to develop a framework that is 280 generalizable and not to determine a general value of Γ. The value of such an optimization framework is to provide the decision maker with flexibility to tailor a robust solution for the particular patient at hand. Note that an appropriate value of Γ will depend on the size of the uncertainty set. Future research could examine using this framework to identify certain "classes" of patients with similar characteristics that can utilize a similar value of Γ.
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Many robust optimization approaches exist in the IMRT and IMPT literature that are conceptually similar to our approach in that they construct a model for the underlying uncertain phenomenon and incorporate this model into the optimization. All of these approaches have the common goal of desensitizing the resulting solution (i.e., fluence map) to the uncertainty. One distinguishing feature of the approach in this paper is our use of Γ to model 290 a budget of uncertainty in an auxiliary problem, whose optimal solution is provided as input into the primary model. Though such a robust model has been applied in other domains, this is the first application of such a model in radiation therapy optimization.
Since the CTV adds a margin around the gross tumor volume (GTV), it includes part of the non-PET avid region due to the presumed low clonogen density expected in microscopic 
V. Conclusion
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In this paper, we present the first robust optimization model for functional image guided IMRT, aimed at mitigating the effects of uncertainty in the PET signal. In our model, we assume voxels in the CTV have a nominal SUV from which they can deviate. Our model uses a simplified treatment planning formulation that gives the treatment planner an adjustable parameter that can be used to adjust the conservatism of the resulting solution. The following theoretical framework, based on several models in the literature, [13] generates a heterogeneous desired dose distribution from PET SUV values and allows us to evaluate our models performance. This is not meant to represent a clinically validated function to map PET values to dose. Of course, should such a relationship be discovered in the future, our framework would be readily able to accept the "true" conversion function. Note 495 that the optimization model only requires the dose distribution and does not depend on any biological function.
To generate the desired dose for each voxel, we start with an observed SUV value, convert it to a normalized biological feature, generate the α, β parameters of the linear quadratic model of cell kill (LQ), and finally compute the voxel-specific desired dose needed to achieve 500 a certain TCP.
A. Radiobiological modeling
We calculate the tumor control probability of voxel i, TCP i , according to the LQ model. [2, 11, 13, 42] TCP i is given by: 
B. Conversion from SUV to voxel-specific desired dose
While the true function to convert FDG SUV to a desired dose is unknown, we will 510 assume a particular functional form for the purposes of model evaluation. The optimization is independent of the dose function; it only assumes that a dose can be calculated given the SUV. The dose distribution will be derived to maximize the TCP under the LQ model.
We will assume that the normalized biological feature in this case is oxygenation. Following South et al. [13] , we assume that the PET signal is negatively correlated to oxygenation.
First, we convert SUV θ i , to oxygenation p(θ i ), according to the following equation:
Parameters p min and p max were chosen to be 1 and 100, respectively. The function p(θ i ) is shown in Figure 4 (a). We chose parameters φ 1 and φ 2 to fit the overall relationship between 515 SUV and dose so that at a SUV of 2.5 the dose would be approximately 67 Gy and at a SUV of 20, the dose would be approximately 105 Gy (see Figure 4(d) ). The values chosen for φ 1 , φ 2 were 1 and 14, respectively. An SUV of 2.5 was used because it is a commonly used threshold for tumor delineation. [43] We recognize that a simple threshold for delineation has a number of issues regarding variability. While normalized SUV (N-SUV) is an approach 520 that attempts to reduce potential variations in the measurement, such as varying blood glucose levels, [44] precautions have been taken pre-emptively to avoid effects in our imaging protocol (i.e., patient fasting, controlled blood glucose levels). It should also be noted that a number of SUV thresholds have been validated with surgical samples. [45, 46] For each voxel i, we convert partial oxygen pressure into the factors, A i and B i , which modify the intrinsic radiosensitivity parameters, α i and β i , respectively, [47, 48] according to the following equations:
Parameters OER αmax and OER βmax are the maximum oxygen enhancement ratios (OER)
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for α and β, respectively. [10] Parameter K m is the partial oxygen pressure at which halfmaximum sensitization is reached and p i is the partial oxygen pressure for voxel i. To derive voxel-specific radiosensitivity parameters α i and β i , the intrinsic parameters, α and β, are then multiplied by their respective A i and B i : α i = A i α and β i = B i β. Figure 4(b) shows the relationship between oxygenation and the LQ parameters.
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The modified radiosensitivity parameters determine a voxel-specific dose that results in a specified TCP, according to the method described by Yang and Xing [11] . For this study, the intrinsic radiobiological parameters for the lung tumor were set as follows [13, 49, 50] : ρ = 10 7 clonogens/cm 3 , α = 0.35 Gy −1 , β = 0.035, α β = 10, T p = 3 days (equivalent to a cell proliferation rate of 0.1386 days −1 ), OER αmax = 2.5, OER βmax = 3, K m = 3.28, T k = 28 days. Partial oxygen pressure for a voxel was assumed to be bounded within the range p ∈ [1, 100] mmHg. [13] The treatment plan parameters were set as follows:
